275
Participants
Start Date
May 31, 2007
Primary Completion Date
April 30, 2013
Study Completion Date
November 30, 2013
Docetaxel
"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
Vinorelbine
DV Group: 35 mg/m\^2 on days 1 and 15
Carboplatin
"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
Gemcitabine
"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
Johns Hopkins Sidney Kimmell Comprehensive Cancer Center, Baltimore
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Center for Cancer Care & Research/Watson, Lakeland
Leesburg Regional Medical Center, Leesburg
Barbara Ann Karmanos Cancer Institute, Detroit
Klinik Loewenstein, Löwenstein
Southeast Nebraska Cancer Center, Lincoln
Fox Chase Cancer Center, Philadelphia
Ponce School of Medicine, Ponce
Collaborators (1)
Sanofi
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER